Spruce Biosciences, Inc. (SPRB)

NASDAQ: SPRB · IEX Real-Time Price · USD

0.525

-0.021 (-3.83%)

At close: Jul 19, 2024, 4:00 PM

0.524

-0.001 (-0.23%)

Pre-market: Jul 22, 2024, 7:41 AM EDT

Spruce Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Revenue	10.13	10.09	0	0	0	0	Upgrade
Revenue Growth (YoY)	415.63%	-	-	-	-	-	Upgrade
Gross Profit	10.13	10.09	0	0	0	0	Upgrade
Selling, General & Admin	13.52	12.65	12.09	11.37	5.56	2.29	Upgrade
Research & Development	48.04	49.43	35.2	30.7	23.85	10.82	Upgrade
Operating Expenses	61.55	62.08	47.28	42.07	29.42	13.11	Upgrade
Operating Income	-51.43	-51.99	-47.28	-42.07	-29.42	-13.11	Upgrade
Interest Expense / Income	-0.66	0.48	0.42	0.35	0.32	0.07	Upgrade
Other Expense / Income	-4.02	-4.56	-1.52	-0.12	-0.2	-0.08	Upgrade
Pretax Income	-46.75	-47.92	-46.18	-42.29	-29.54	-13.09	Upgrade
Net Income	-46.75	-47.92	-46.18	-42.29	-29.54	-13.09	Upgrade
Shares Outstanding (Basic)	41	39	24	23	6	1	Upgrade
Shares Outstanding (Diluted)	41	39	24	23	6	1	Upgrade
Shares Change	28.83%	63.68%	0.71%	289.93%	683.77%	-84.44%	Upgrade
EPS (Basic)	-1.13	-1.24	-1.96	-1.81	-4.93	-17.12	Upgrade
EPS (Diluted)	-1.13	-1.24	-1.96	-1.81	-4.93	-17.12	Upgrade
Free Cash Flow	-36.45	-33.28	-41.69	-35.97	-27.59	-12.62	Upgrade
Free Cash Flow Per Share	-0.89	-0.86	-1.77	-1.54	-4.61	-16.51	Upgrade
Gross Margin	100.00%	100.00%	-	-	-	-	Upgrade
Operating Margin	-507.82%	-515.34%	-	-	-	-	Upgrade
Profit Margin	-461.67%	-474.96%	-	-	-	-	Upgrade
Free Cash Flow Margin	-359.93%	-329.88%	-	-	-	-	Upgrade
EBITDA	-47.11	-47.14	-45.33	-41.57	-29.11	-13.01	Upgrade
EBITDA Margin	-465.20%	-467.20%	-	-	-	-	Upgrade
Depreciation & Amortization	0.3	0.3	0.43	0.38	0.1	0.01	Upgrade
EBIT	-47.41	-47.44	-45.76	-41.95	-29.22	-13.02	Upgrade
EBIT Margin	-468.14%	-470.18%	-	-	-	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).